Metformin as an anti-aging drug: promising mechanisms but insufficient evidence

Current data on metformin as a geroprotector reveals a troubling gap between its proven efficacy in metabolic syndrome and its actual capacity to decelerate aging. At the molecular level, metformin activates AMPK, suppressing mTOR, boosting mitochondrial biogenesis and autophagy, and reshaping the gut microbiota toward short-chain fatty acid-producing bacteria. Yet the landmark TAME trial, designed to evaluate metformin in 3,000 non-diabetic participants aged 65-79 over four years, remains unpublished since launching in 2017 and is now under ARPA-H stewardship. The MeMeMe trial did document 80-92% reductions in type 2 diabetes at 1,700 mg/day metformin across 1,400 metabolic syndrome patients, but found no preventive benefit for cancer, cardiovascular disease, or mortality. For the longevity-focused reader, the verdict is straightforward: metformin works robustly as an antidiabetic, yet evidence for systemic aging delay remains mixed in animal studies and essentially absent in recent human data.